• LAST PRICE
    25.5400
  • TODAY'S CHANGE (%)
    Trending Up1.0800 (4.4154%)
  • Bid / Lots
    25.5000/ 4
  • Ask / Lots
    25.5900/ 4
  • Open / Previous Close
    24.4200 / 24.4600
  • Day Range
    Low 24.3500
    High 25.7600
  • 52 Week Range
    Low 13.5700
    High 53.0800
  • Volume
    202,038
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 24.46
TimeVolumeARVN
09:32 ET749324.37
09:34 ET20024.37
09:36 ET30024.365
09:38 ET100024.35
09:39 ET20024.39
09:41 ET735824.535
09:43 ET90024.63
09:45 ET609524.735
09:48 ET101724.74
09:50 ET100024.83
09:52 ET125024.895
09:54 ET489024.995
09:56 ET510025.065
09:57 ET517625.12
09:59 ET636925.01
10:03 ET90025.135
10:06 ET50025.155
10:08 ET270025.25
10:10 ET70025.27
10:12 ET250925.34
10:14 ET512025.215
10:15 ET892725.22
10:17 ET120025.3
10:19 ET273125.245
10:21 ET90025.275
10:24 ET50025.325
10:26 ET90025.28
10:28 ET221525.31
10:30 ET337525.255
10:32 ET30025.23
10:33 ET480525.255
10:35 ET40025.255
10:37 ET335525.255
10:39 ET488425.235
10:42 ET70025.24
10:44 ET638825.27
10:46 ET120025.38
10:48 ET204725.4
10:50 ET223525.555
10:51 ET319225.57
10:53 ET360625.505
10:55 ET292925.515
10:57 ET120025.595
11:00 ET535725.53
11:02 ET60025.525
11:04 ET1131325.515
11:06 ET114125.6025
11:08 ET101125.615
11:09 ET410425.64
11:11 ET50025.605
11:13 ET40025.605
11:15 ET41825.55
11:18 ET50025.55
11:20 ET194625.54
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesARVN
Arvinas Inc
1.7B
-4.2x
---
United StatesKYMR
Kymera Therapeutics Inc
1.9B
-12.2x
---
United StatesPTGX
Protagonist Therapeutics Inc
1.9B
12.6x
---
United StatesNRIX
Nurix Therapeutics Inc
1.2B
-7.7x
---
United StatesIMTX
Immatics NV
1.2B
-11.3x
---
United StatesVIR
Vir Biotechnology Inc
1.3B
-2.3x
---
As of 2024-06-26

Company Information

Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.

Contact Information

Headquarters
5 Science ParkNEW HAVEN, CT, United States 06511-1966
Phone
203-535-1456
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
John Houston
Chief Financial Officer, Treasurer
Andrew Saik
President - Research and Development
Ian Taylor
Chief Scientific Officer
Angela Cacace
General Counsel
Jared Freedberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$1.7B
Revenue (TTM)
$71.3M
Shares Outstanding
68.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.98
EPS
$-6.05
Book Value
$9.71
P/E Ratio
-4.2x
Price/Sales (TTM)
23.5
Price/Cash Flow (TTM)
---
Operating Margin
-556.94%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.